Generic Drugmaking Firms Fall Short for Poorest Patients
Writing for Bloomberg, Chris Kay covers the launch of the Foundation's first report from its Generic & Biosimilar Medicines programme. The report consists of in-depth profiles of five major manufacturers, assessing them on their efforts to expand access to their products in low- and middle-income countries, and outlining opportunities to make further impact.
The article focuses on the shortfalls by these companies, pulling out the statistic from the report that only one product, out of the 50 in scope that are produced by the manufacturers assessed, includes a pricing strategy that takes affordability into account.
The article notes that the report provides clear opportunities for companies to ramp up their efforts and make it easier for people living in low- and middle-income countries to get the medicines they need.
Read the Foundation's report on generic and biosimilar medicine manufacturers.